Australian Pharma Stock News

Vault Minerals Limited recently reported full-year results for the 12 months to June 30, 2026, with sales of A$1,926.61 million and net income of A$278.41 million, both higher than the prior year. Basic earnings per share from continuing operations rose to A$0.267, underscoring improved profitability and operational efficiency across the business. We’ll now look at how this earnings growth, particularly the rise in net income, shapes Vault Minerals’ broader investment narrative. We've...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Clinuvel Pharmaceuticals closed at A$8.47 after a weak few months for the stock, with the share price down over the past week, month and quarter. Yet the latest full year numbers tell a calmer story. The company delivered around A$94.0m in trailing twelve month revenue with a net profit margin near 36%. That kind of profitability is unusual in biotech and underpins a trailing P/E of 12.6x that sits well below peers. For long term holders, the key point is that this remains a highly...

Insiders who purchased AU$1.36m worth of Credit Clear Limited ( ASX:CCR ) shares over the past year recouped some of...

McMillan Shakespeare stock has been grinding higher in recent months, yet the real story today is not the share price at A$20.87. The real story is a profit engine that just posted record underlying net profit after tax and amortisation of A$107.9m and a fatter 41.5% operating margin in a year that was meant to be tougher for salary packaging and fleet services. For investors, the kicker is the cash being returned. The board signed off on a fully franked full year dividend of A$1.32 per...

Botanix Pharmaceuticals Limited ( ASX:BOT ) just released its latest yearly report and things are not looking great. It...

Emerald Resources NL ( ASX:EMR ) came out with its yearly results last week, and we wanted to see how the business is...

It looks like Monadelphous Group Limited ( ASX:MND ) is about to go ex-dividend in the next four days. The ex-dividend...

Some investors rely on dividends for growing their wealth, and if you're one of those dividend sleuths, you might be...

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Weebit Nano shareholders have watched the stock slide in recent months, with the price now at A$3.75 after a tough 90 days. Today's full year numbers keep that pressure squarely on profitability. Revenue for FY 2026 remains modest at A$15.28m on a trailing twelve month basis, while losses from continuing operations widened to A$54.90m. For a pre revenue scale semiconductor player, this earnings release focuses on how long the company can fund that loss profile and how investors balance the...

Shaver Shop Group went into this result priced like a value play, with the stock at A$1.41 and a P/E of 12.5x that sat below peer and industry averages. The headline from the numbers is not a growth surge. It is a tension between record sales of A$225.1m and record gross margin of 46.3% on one side and essentially flat net profit after tax of A$14.8m on the other. That mix sets up a classic sentiment test. Traders focused only on headline records might cheer, while investors watching a 90%...

Actinogen Medical entered this earnings season as a high risk biotech stock with a thin cash cushion and an unprofitable track record. The share price now trades at A$0.044 after a weak 7 day run and a stronger 3 month climb. The headline from this FY 2026 release is the pressure on the balance sheet. Management reported a loss of A$15.4 million over the trailing 12 months with no clear profitability in view and less than one year of cash runway. Concerned by Actinogen Medical's cash runway...

It's been a pretty great week for Perseus Mining Limited ( ASX:PRU ) shareholders, with its shares surging 10% to...

Why Sonic Healthcare’s latest earnings and dividend matter now Sonic Healthcare (ASX:SHL) has drawn fresh attention after releasing full year 2026 results, confirming higher revenue and net income than a year earlier, alongside a declared dividend for the June half. Sonic Healthcare’s share price has softened in the short term, with a 7 day share price return of 4.93% and a 30 day share price return of 11.8% down to A$20.04. The 1 year total shareholder return has declined 12.74%, pointing to...

Intelligent Monitoring Group closed at A$0.645 today, barely moved over the past week, even as the latest result quietly shifted the story. The headline is simple. This security and monitoring stock has flipped from a loss in the first half to a full year in the black, with A$3.43m of second half net income and operating cash roughly doubling to around A$22m. The short term share price reaction looks muted. The long term question now is whether this early turn in profitability and cash...

Horizon Oil entered this result period with the stock down over the past week and quarter, yet still on a punchy 24.2x trailing P/E. The market clearly treated the shares as a higher multiple oil and gas story, then watched a small stock trading at A$0.22 deliver a year where free cash flow and profitability became the headline. The key factor this time is the balance sheet and cash engine. Horizon Oil finished FY26 with US$37.4m in cash, modest net debt of US$11.3m and free cash flow of...

Harvey Norman Holdings stock has been grinding lower for weeks, with the share price down about 12% over the past month and closing at A$4.42. Yet the fresh earnings story is less about a collapsing business and more about a slow squeeze on profitability. Revenue over the last twelve months sits above A$3.0b, but net profit margin has edged back to 17.3% and trailing earnings have softened. The immediate question for you now is simple: Is this a value opportunity on a low P/E, or a warning...

Santos (ASX:STO) has released half year results showing net income of US$355 million and a lower earnings per share figure than a year earlier. The company also affirmed an interim dividend of US$0.116 per share. At a share price of A$8.12, Santos has seen a 32.03% year to date share price return, while the 1 year total shareholder return of 8.20% and 5 year total shareholder return of 64.47% point to gains built over a longer period. Recent dividend announcements and the half year earnings...

Ashley Services Group Limited ( ASX:ASH ) insiders who purchased shares in the last 12 months were richly rewarded last...

Generation Development Group came into this result with a stock that has been sliding, down about 23% over the past month and about 22% over three months, and trading on a rich trailing P/E of 40.1x. That set a high bar. The headline from FY 2026 is clear. Underlying profit stepped up, with group net income of A$25.1m in the second half and A$6.9m in the first half, backed by A$583.7m in trailing twelve month revenue. The market is now weighing those earnings against an elevated valuation and...

Bapcor walked into this result with a stock that had already bounced hard, up more than 65% over the past three months to about A$0.705. Yet the headline numbers are still all about repair rather than reward. The market is pricing a turnaround story. The earnings print shows a very different reality. Revenue for FY26 landed at about A$1.924b while the company reported a statutory loss of A$431.6m driven largely by impairment charges. For you as an investor, the key angle is profit pressure...

Objective shareholders came into this result already on the back foot, with the stock down around 35% over the past three months and closing at A$6.80 ahead of digesting the full year story. The earnings headline is not about a blow up in profit. It is about how the market squares that slump in sentiment with a software company reporting A$134.7m in revenue, A$37.2m in net profit and an adjusted EBITDA margin near 39%. The key question now is whether that earnings power and a fully franked...